|
|
| | PUROMYCIN AMINONUCLEOSIDE Basic information |
| Product Name: | PUROMYCIN AMINONUCLEOSIDE | | Synonyms: | 3’-amino-3’-deoxy-n,n-dimethyl-adenosin;6-(dimethylamino)-9-(3-amino-3-deoxy-beta-d-ribofuranosyl)purine;9-(3-amino-3-deoxy-beta-d-ribofuranosyl)-6-(dimethylamino)-9h-purine;aminonucleoside;aminonucleosidepuromycin;stylomycinaminonucleoside;PUROMYCIN AMINONUCLEOSIDE;6-DIMETHYLAMIN-9-[3'-AMINO-3'DEOXYRIBOSYL]-PURINE | | CAS: | 58-60-6 | | MF: | C12H18N6O3 | | MW: | 294.31 | | EINECS: | 200-388-3 | | Product Categories: | | | Mol File: | 58-60-6.mol |  |
| | PUROMYCIN AMINONUCLEOSIDE Chemical Properties |
| Melting point | 235℃ (Decomposition) | | Boiling point | 436.08°C (rough estimate) | | density | 1.2131 (rough estimate) | | refractive index | 1.7000 (estimate) | | Fp | >110°(230°F) | | storage temp. | Keep in dark place,Inert atmosphere,2-8°C | | solubility | H2O: 50 mg/mL, clear, slightly yellow | | form | liquid | | pka | 13.26±0.70(Predicted) | | color | White | | Water Solubility | Soluble in water at 50mg/ml. May require heating | | BRN | 93902 | | Stability: | Stable for 1 year as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 2 months. | | InChIKey | RYSMHWILUNYBFW-GRIPGOBMSA-N | | EPA Substance Registry System | Adenosine, 3'-amino-3'-deoxy-N,N-dimethyl- (58-60-6) |
| Hazard Codes | Xi,Xn | | Risk Statements | 48/22 | | WGK Germany | 3 | | RTECS | AU7337000 | | F | 10-21 | | TSCA | Yes | | HS Code | 29419090 |
| | PUROMYCIN AMINONUCLEOSIDE Usage And Synthesis |
| Description | Puromycin aminonucleoside (58-60-6) is the nucleoside moiety of puromycin (Cat.# 10-2100) which does not inhibit protein synthesis or induce apoptosis.1?It acts as a glomerular epithelial cell toxin2 and as such is a useful tool for producing animal models of nephropathy3,4, or puromycin aminonucleoside nephrosis (1-2.5 mg/100g rat body weight)5. Active in vivo. | | Chemical Properties | White crystal | | Uses | Puromycin aminonucleoside is a semi-synthetic derivative of puromycin which lacks the methoxyphenylalanyl moiety. Puromycin aminonucleoside is the key intermediate in the synthesis of semi-synthetic analogues of puromycin. It does not inhibit protein synthesis or induce apoptosis, but exhibits antitumour properties. Puromycin aminonucleoside-induced nephrosis is a well-described model of human idiopathic nephrotic syndrome, suppressing integrin expression in cultured glomerular epithelial cells. | | Uses | Puromycin Aminonucleoside is an aminonucleoside portion of the antibiotic puromycin. | | Definition | ChEBI: Puromycin derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. | | Safety Profile | An experimental teratogen. Other experimental reproductive effects. Human mutation data reported. When heated to decomposition it emits toxic fumes of NOx,. | | References | 1) Chow et al. (1995), Reevaluation of the role of de novo protein synthesis in rat thymocyte apoptosis; Exp. Cell Res., 216 149
2) Krishnamurti et al. (2001), Puromycin aminonucleoside suppresses integrin expression in cultured glomerular epithelial cells; J. Am. Soc. Nephrol., 12 758
3) Egashira et al. (2006), Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis; Int. J. Vitam. Nutr. Res., 76 28
4) Hagiwara et al. (2006), Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis; Kidney Int., 69 1146
5) Lowenborg et al. (2000), Glomerular function and morphology in puromycin aminonucleoside nephropathy in rats; Nephrol. Dial. Transplant, 15 1547 |
| | PUROMYCIN AMINONUCLEOSIDE Preparation Products And Raw materials |
|